Altimmune (ALT) Net Income towards Common Stockholders (2010 - 2026)
Altimmune (ALT) reported Net Income towards Common Stockholders of -$22.6 million for Q1 2026, down 15.26% year-over-year from -$26.6 million in Q1 2025, and down 138.98% quarter-over-quarter from $57.9 million in Q4 2025.
Altimmune (ALT) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$22.6 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$22.6 million, down 15.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.8 million (up 93.54% YoY), and the FY2025 annual result was -$2.8 million, up 97.01% from the prior year.
- Net Income towards Common Stockholders fell to -$22.6 million in Q1 2026 per ALT's latest filing, from $57.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $57.9 million in Q4 2025 and troughed at -$24.6 million in Q2 2024.
- A 5-year average of -$11.7 million and a median of -$20.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders surged 1049.28% in 2022, then tumbled 160.71% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $51.1 million in 2022, then slumped by 117.4% to -$8.9 million in 2023, then sank by 160.71% to -$23.2 million in 2024, then jumped by 349.74% to $57.9 million in 2025, then slumped by 138.98% to -$22.6 million in 2026.
- Business Quant data shows ALT's Net Income towards Common Stockholders at -$22.6 million in Q1 2026, $57.9 million in Q4 2025, and -$19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -22.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.56 Mn |
| Dec 31, 2025 | 57.89 Mn |
| Sep 30, 2025 | -19.01 Mn |
| Jun 30, 2025 | -22.15 Mn |
| Mar 31, 2025 | -19.58 Mn |
| Dec 31, 2024 | -23.18 Mn |
| Sep 30, 2024 | -22.85 Mn |
| Jun 30, 2024 | -24.64 Mn |
| Mar 31, 2024 | -24.39 Mn |
| Dec 31, 2023 | -8.89 Mn |
| Sep 30, 2023 | -20.67 Mn |
| Jun 30, 2023 | -16.17 Mn |
| Mar 31, 2023 | -20.09 Mn |
| Dec 31, 2022 | 51.09 Mn |
| Sep 30, 2022 | -23.52 Mn |
| Jun 30, 2022 | -20.13 Mn |
| Mar 31, 2022 | -19.54 Mn |
| Dec 31, 2021 | -5.38 Mn |
| Sep 30, 2021 | -33.51 Mn |
| Jun 30, 2021 | -24.83 Mn |